Barclays’s ASLAN Pharmaceuticals Limited American Depositary Shares ASLN Stock Holding History

Barclays’s Portfolio ASLN Stock Details ASLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,500	Closed	-$219K	–	4744
2023 Q2	$219K	Hold	7,500	–	–	﹤0.01%	3200
2023 Q1	$173K	Sell	7,500 -282	-4%	-$7.63K	﹤0.01%	3876
2022 Q4	$112K	Sell	7,782 -4,000	-34%	-$77.2K	﹤0.01%	4161
2022 Q3	$283K	Sell	11,782 -942	-7%	-$24.3K	﹤0.01%	3014
2022 Q2	$252K	Hold	12,724	–	–	﹤0.01%	3312
2022 Q1	$458K	Hold	12,724	–	–	﹤0.01%	2958
2021 Q4	$570K	Buy	12,724 +8,005	+170%	+$480K	﹤0.01%	3149
2021 Q3	$336K	Buy	4,719 +1,512	+47%	+$172K	﹤0.01%	3372
2021 Q2	$423K	Sell	3,207 -8	-0.2%	-$1K	﹤0.01%	3165
2021 Q1	$431K	Buy	+3,215	New	+$407K	﹤0.01%	3268
2020 Q2	–	Sell	-5	Closed	–	–	6387
2020 Q1	$0	Sell	5 -2	-29%	-$152	﹤0.01%	6553
2019 Q4	$1K	Buy	+7	New	+$500	﹤0.01%	6285

Other funds holding ASLN

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's ASLN Position: Q3 2023 in Review

Barclays sold out of ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) in Q3 2023, closing a stake of 7,500 shares — an estimated $219K sold.

Barclays first reported a position in ASLN in Q4 2019 and held it in 12 quarters. The position peaked at $570K in Q4 2021. 19 funds tracked by Wall St. Rank hold ASLN as of Q3 2023.

Barclays reported no remaining ASLAN Pharmaceuticals Limited American Depositary Shares position as of Q3 2023 after selling out during the quarter.
Barclays sold 7,500 ASLAN Pharmaceuticals Limited American Depositary Shares shares in Q3 2023, an estimated $219K.
Barclays first reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares in Q4 2019 and held it in 12 quarters.
Barclays's ASLAN Pharmaceuticals Limited American Depositary Shares position peaked at $570K in Q4 2021.
19 funds tracked by Wall St. Rank held ASLAN Pharmaceuticals Limited American Depositary Shares as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.